News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
806,305 Results
Type
Article (79293)
Company Profile (541)
Press Release (726471)
Multimedia
Podcasts (127)
Webinars (13)
Section
Business (223789)
Career Advice (3660)
Deals (38268)
Drug Delivery (129)
Drug Development (88892)
Employer Resources (185)
FDA (17678)
Job Trends (16730)
News (381019)
Policy (37546)
Tag
2024 BioCapital Digital (17)
2024 BioForest Digital (12)
2024 BioForest Standard (1)
2024 BioMidwest Digital (11)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (15)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (20)
2024 Biotech Beach Digital (15)
2024 Biotech Beach Standard (9)
2024 Genetown Digital (9)
2024 Genetown Standard (11)
2024 Lone Star Bio Digital (15)
2024 Pharm Country Digital (11)
2024 Pharm Country Standard (6)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (7)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Bio NC Standard (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (3)
2026 Genetown Standard (1)
2026 Pharm Country Elite (1)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (2)
Academia (2993)
Academic (2)
Accelerated approval (6)
Adcomms (29)
Allergies (93)
Alliances (55629)
ALS (99)
Alzheimer's disease (1500)
Antibody-drug conjugate (ADC) (156)
Approvals (17645)
Artificial intelligence (302)
Autoimmune disease (29)
Automation (16)
Bankruptcy (381)
Best Places to Work (12578)
BIOSECURE Act (22)
Biosimilars (119)
Biotechnology (375)
Bladder cancer (84)
Brain cancer (32)
Breast cancer (303)
Cancer (2429)
Cardiovascular disease (203)
Career advice (3112)
Career pathing (34)
CAR-T (172)
Cell therapy (485)
Cervical cancer (21)
Clinical research (71591)
Collaboration (910)
Compensation (537)
Complete response letters (30)
COVID-19 (2864)
CRISPR (48)
C-suite (262)
Cystic fibrosis (107)
Data (2257)
Decentralized trials (2)
Denatured (44)
Depression (54)
Diabetes (294)
Diagnostics (6884)
Digital health (20)
Diversity (9)
Diversity, equity & inclusion (44)
Drug discovery (137)
Drug pricing (126)
Drug shortages (33)
Duchenne muscular dystrophy (101)
Earnings (91692)
Editorial (44)
Employer branding (25)
Employer resources (162)
Events (125487)
Executive appointments (772)
FDA (18984)
Featured Employer (64)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (8)
Funding (808)
Gene editing (119)
Generative AI (30)
Gene therapy (354)
GLP-1 (843)
Government (5137)
Grass and pollen (6)
Guidances (59)
Healthcare (20817)
Huntington's disease (24)
IgA nephropathy (31)
Immunology and inflammation (144)
Indications (30)
Infectious disease (3025)
Inflammatory bowel disease (152)
Inflation Reduction Act (11)
Influenza (57)
Intellectual property (101)
Interviews (705)
IPO (17435)
IRA (51)
Job creations (4633)
Job search strategy (2543)
Kidney cancer (11)
Labor market (34)
Layoffs (546)
Leadership (24)
Legal (9424)
Liver cancer (81)
Lung cancer (345)
Lymphoma (158)
Machine learning (7)
Management (65)
Manufacturing (345)
MASH (74)
Medical device (14494)
Medtech (14499)
Mergers & acquisitions (21391)
Metabolic disorders (780)
Multiple sclerosis (87)
NASH (23)
Neurodegenerative disease (114)
Neuropsychiatric disorders (34)
Neuroscience (2101)
NextGen: Class of 2025 (7561)
Non-profit (5072)
Northern California (2736)
Now hiring (40)
Obesity (420)
Opinion (273)
Ovarian cancer (78)
Pain (97)
Pancreatic cancer (86)
Parkinson's disease (160)
Partnered (23)
Patents (250)
Patient recruitment (114)
Peanut (51)
People (63124)
Pharmaceutical (115)
Pharmacy benefit managers (21)
Phase I (22193)
Phase II (31216)
Phase III (23489)
Pipeline (1236)
Policy (169)
Postmarket research (3255)
Preclinical (10013)
Press Release (72)
Prostate cancer (113)
Psychedelics (38)
Radiopharmaceuticals (269)
Rare diseases (429)
Real estate (6999)
Recruiting (75)
Regulatory (25287)
Reports (41)
Research institute (2648)
Resumes & cover letters (583)
Rett syndrome (5)
RNA editing (5)
RSV (50)
Schizophrenia (80)
Series A (141)
Series B (91)
Service/supplier (22)
Sickle cell disease (58)
Southern California (2368)
Special edition (18)
Spinal muscular atrophy (166)
Sponsored (34)
Startups (4151)
State (2)
Stomach cancer (16)
Supply chain (76)
Tariffs (44)
The Weekly (81)
United States (24428)
Vaccines (807)
Venture capitalists (44)
Weight loss (301)
Women's health (40)
Worklife (20)
Date
Today (151)
Last 7 days (921)
Last 30 days (2802)
Last 365 days (35289)
2025 (11420)
2024 (37732)
2023 (42479)
2022 (53844)
2021 (58609)
2020 (57537)
2019 (51145)
2018 (38988)
2017 (36469)
2016 (37142)
2015 (43155)
2014 (37443)
2013 (33788)
2012 (35564)
2011 (35530)
2010 (35023)
Location
Africa (1180)
Alabama (60)
Alaska (7)
Arizona (250)
Arkansas (14)
Asia (47764)
Australia (8255)
California (6392)
Canada (2048)
China (560)
Colorado (280)
Connecticut (297)
Delaware (156)
Europe (108230)
Florida (935)
Georgia (215)
Idaho (62)
Illinois (601)
India (29)
Indiana (328)
Iowa (11)
Japan (168)
Kansas (109)
Kentucky (26)
Louisiana (12)
Maine (70)
Maryland (952)
Massachusetts (4885)
Michigan (242)
Minnesota (411)
Mississippi (2)
Missouri (88)
Montana (31)
Nebraska (26)
Nevada (65)
New Hampshire (70)
New Jersey (1800)
New Mexico (31)
New York (1802)
North Carolina (1106)
North Dakota (9)
Northern California (2736)
Ohio (216)
Oklahoma (15)
Oregon (43)
Pennsylvania (1411)
Puerto Rico (13)
Rhode Island (35)
South America (1553)
South Carolina (23)
South Dakota (1)
Southern California (2368)
Tennessee (104)
Texas (942)
Utah (189)
Virginia (163)
Washington D.C. (68)
Washington State (591)
West Virginia (3)
Wisconsin (66)
806,305 Results for "johnson and johnson pharmaceutical research and development llc ca".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
April 21, 2025
·
10 min read
Press Releases
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
April 28, 2025
·
9 min read
Press Releases
Johnson & Johnson’s TAR-200 monotherapy demonstrates highest complete response rate reported to date with sustained clinical benefits in patients with certain types of bladder cancer
April 28, 2025
·
11 min read
Press Releases
TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease
April 25, 2025
·
14 min read
Press Releases
Johnson & Johnson MedTech Announces Completion of First Cases with OTTAVA™ Robotic Surgical System
April 14, 2025
·
6 min read
Press Releases
Johnson & Johnson Reports Q1 2025 Results
April 15, 2025
·
23 min read
Press Releases
TuHURA Biosciences, Inc Appoints Craig L. Tendler M.D., Former Vice President, Oncology Clinical Development, Diagnostics, and Global Medical Affairs, Johnson & Johnson Innovative Medicine Research & Development, to its Board of Directors
March 12, 2025
·
8 min read
Press Releases
Johnson & Johnson to Present New Data for TECNIS Odyssey, The Fastest Growing PCIOL in the U.S^, at ASCRS 2025
April 28, 2025
·
9 min read
European Commission approves Johnson & Johnson’s subcutaneous DARZALEX® (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
April 7, 2025
·
14 min read
Press Releases
Johnson & Johnson’s TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
April 28, 2025
·
10 min read
1 of 80,631
Next
